Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant

Detalhes bibliográficos
Autor(a) principal: Brandao, Ajacio Bandeira de Mello
Data de Publicação: 2022
Outros Autores: Rodríguez, Santiago, Fleck Júnior, Alfeu de Medeiros, Marroni, Claudio Augusto, Wagner, Mario Bernardes, Horbe, Alex Finger, Fernandes, Matheus Vanzin, Cerski, Carlos Thadeu Schmidt, Coral, Gabriela Perdomo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/266990
Resumo: BACKGROUND Cholangiocarcinoma (CC) is a rare tumor that arises from the epithelium of the bile ducts. It is classified according to anatomic location as intrahepatic, perihilar, and distal. Intrahepatic CC (ICC) is rare in patients with cirrhosis due to causes other than primary sclerosing cholangitis. Mixed hepatocellular carcinoma-CC (HCC-CC) is a rare neoplasm that shows histologic findings of both HCC and ICC within the same tumor mass. Due to the difficulties in arriving at the correct diagnosis, patients eventually undergo liver transplantation (LT) with a presumptive diagnosis of HCC on imaging when, in fact, they have ICC or HCC-CC. AIM To evaluate the outcomes of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma on pathological examination after liver transplant. METHODS Propensity score matching was used to analyze tumor recurrence (TR), overall mortality (OM), and recurrence-free survival (RFS) in LT recipients with pathologically confirmed ICC or HCC-CC matched 1:8 to those with HCC. Progression-free survival and overall mortality rates were computed with the Kaplan-Meier method using Cox regression for comparison. RESULTS Of 475 HCC LT recipients, 1.7% had the diagnosis of ICC and 1.5% of HCC-CC on pathological examination of the explant. LT recipients with ICC had higher TR (46% vs 11%; P = 0.006), higher OM (63% vs 23%; P = 0.002), and lower RFS (38% vs 89%; P = 0.002) than those with HCC when matched for pretransplant tumor characteristics, as well as higher TR (46% vs 23%; P = 0.083), higher OM (63% vs 35%; P = 0.026), and lower RFS (38% vs 59%; P = 0.037) when matched for posttransplant tumor characteristics. Two pairings were performed to compare the outcomes of LT recipients with HCC-CC vs HCC. There was no significant difference between the outcomes in either pairing. CONCLUSION Patients with ICC had worse outcomes than patients undergoing LT for HCC. The outcomes of patients with HCC-CC did not differ significantly from those of patients with HCC.
id UFRGS-2_69926c6402281c6088c02f41d05ee9c2
oai_identifier_str oai:www.lume.ufrgs.br:10183/266990
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Brandao, Ajacio Bandeira de MelloRodríguez, SantiagoFleck Júnior, Alfeu de MedeirosMarroni, Claudio AugustoWagner, Mario BernardesHorbe, Alex FingerFernandes, Matheus VanzinCerski, Carlos Thadeu SchmidtCoral, Gabriela Perdomo2023-11-11T03:24:22Z20222218-4333http://hdl.handle.net/10183/266990001186996BACKGROUND Cholangiocarcinoma (CC) is a rare tumor that arises from the epithelium of the bile ducts. It is classified according to anatomic location as intrahepatic, perihilar, and distal. Intrahepatic CC (ICC) is rare in patients with cirrhosis due to causes other than primary sclerosing cholangitis. Mixed hepatocellular carcinoma-CC (HCC-CC) is a rare neoplasm that shows histologic findings of both HCC and ICC within the same tumor mass. Due to the difficulties in arriving at the correct diagnosis, patients eventually undergo liver transplantation (LT) with a presumptive diagnosis of HCC on imaging when, in fact, they have ICC or HCC-CC. AIM To evaluate the outcomes of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma on pathological examination after liver transplant. METHODS Propensity score matching was used to analyze tumor recurrence (TR), overall mortality (OM), and recurrence-free survival (RFS) in LT recipients with pathologically confirmed ICC or HCC-CC matched 1:8 to those with HCC. Progression-free survival and overall mortality rates were computed with the Kaplan-Meier method using Cox regression for comparison. RESULTS Of 475 HCC LT recipients, 1.7% had the diagnosis of ICC and 1.5% of HCC-CC on pathological examination of the explant. LT recipients with ICC had higher TR (46% vs 11%; P = 0.006), higher OM (63% vs 23%; P = 0.002), and lower RFS (38% vs 89%; P = 0.002) than those with HCC when matched for pretransplant tumor characteristics, as well as higher TR (46% vs 23%; P = 0.083), higher OM (63% vs 35%; P = 0.026), and lower RFS (38% vs 59%; P = 0.037) when matched for posttransplant tumor characteristics. Two pairings were performed to compare the outcomes of LT recipients with HCC-CC vs HCC. There was no significant difference between the outcomes in either pairing. CONCLUSION Patients with ICC had worse outcomes than patients undergoing LT for HCC. The outcomes of patients with HCC-CC did not differ significantly from those of patients with HCC.application/pdfengWorld journal of clinical oncology. Pleasanton. Vol. 13, no. 8 (Aug. 2022), p. 688-701Transplante de fígadoPrognósticoCarcinoma hepatocelularColangiocarcinomaCholangiocarcinomaHepatocellular carcinomaLiverPrognosisRecurrenceSurvival analysisTransplantationPropensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplantEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001186996.pdf.txt001186996.pdf.txtExtracted Texttext/plain51260http://www.lume.ufrgs.br/bitstream/10183/266990/3/001186996.pdf.txt1774c56d95828b25a9a1f30a95fcaa78MD53001186996-02.pdf.txt001186996-02.pdf.txtExtracted Texttext/plain7501http://www.lume.ufrgs.br/bitstream/10183/266990/4/001186996-02.pdf.txtf12c049d57793f52dc88862f548fcf8bMD54ORIGINAL001186996.pdfTexto completo (inglês)application/pdf1552042http://www.lume.ufrgs.br/bitstream/10183/266990/1/001186996.pdfe0714ec145e85479ecd096ecad7b7c59MD51001186996-02.pdfErrataapplication/pdf714918http://www.lume.ufrgs.br/bitstream/10183/266990/2/001186996-02.pdf11dd34907c5d691e40a01d993a98228cMD5210183/2669902023-11-12 04:23:44.462705oai:www.lume.ufrgs.br:10183/266990Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-11-12T06:23:44Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
title Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
spellingShingle Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
Brandao, Ajacio Bandeira de Mello
Transplante de fígado
Prognóstico
Carcinoma hepatocelular
Colangiocarcinoma
Cholangiocarcinoma
Hepatocellular carcinoma
Liver
Prognosis
Recurrence
Survival analysis
Transplantation
title_short Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
title_full Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
title_fullStr Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
title_full_unstemmed Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
title_sort Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
author Brandao, Ajacio Bandeira de Mello
author_facet Brandao, Ajacio Bandeira de Mello
Rodríguez, Santiago
Fleck Júnior, Alfeu de Medeiros
Marroni, Claudio Augusto
Wagner, Mario Bernardes
Horbe, Alex Finger
Fernandes, Matheus Vanzin
Cerski, Carlos Thadeu Schmidt
Coral, Gabriela Perdomo
author_role author
author2 Rodríguez, Santiago
Fleck Júnior, Alfeu de Medeiros
Marroni, Claudio Augusto
Wagner, Mario Bernardes
Horbe, Alex Finger
Fernandes, Matheus Vanzin
Cerski, Carlos Thadeu Schmidt
Coral, Gabriela Perdomo
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Brandao, Ajacio Bandeira de Mello
Rodríguez, Santiago
Fleck Júnior, Alfeu de Medeiros
Marroni, Claudio Augusto
Wagner, Mario Bernardes
Horbe, Alex Finger
Fernandes, Matheus Vanzin
Cerski, Carlos Thadeu Schmidt
Coral, Gabriela Perdomo
dc.subject.por.fl_str_mv Transplante de fígado
Prognóstico
Carcinoma hepatocelular
Colangiocarcinoma
topic Transplante de fígado
Prognóstico
Carcinoma hepatocelular
Colangiocarcinoma
Cholangiocarcinoma
Hepatocellular carcinoma
Liver
Prognosis
Recurrence
Survival analysis
Transplantation
dc.subject.eng.fl_str_mv Cholangiocarcinoma
Hepatocellular carcinoma
Liver
Prognosis
Recurrence
Survival analysis
Transplantation
description BACKGROUND Cholangiocarcinoma (CC) is a rare tumor that arises from the epithelium of the bile ducts. It is classified according to anatomic location as intrahepatic, perihilar, and distal. Intrahepatic CC (ICC) is rare in patients with cirrhosis due to causes other than primary sclerosing cholangitis. Mixed hepatocellular carcinoma-CC (HCC-CC) is a rare neoplasm that shows histologic findings of both HCC and ICC within the same tumor mass. Due to the difficulties in arriving at the correct diagnosis, patients eventually undergo liver transplantation (LT) with a presumptive diagnosis of HCC on imaging when, in fact, they have ICC or HCC-CC. AIM To evaluate the outcomes of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma on pathological examination after liver transplant. METHODS Propensity score matching was used to analyze tumor recurrence (TR), overall mortality (OM), and recurrence-free survival (RFS) in LT recipients with pathologically confirmed ICC or HCC-CC matched 1:8 to those with HCC. Progression-free survival and overall mortality rates were computed with the Kaplan-Meier method using Cox regression for comparison. RESULTS Of 475 HCC LT recipients, 1.7% had the diagnosis of ICC and 1.5% of HCC-CC on pathological examination of the explant. LT recipients with ICC had higher TR (46% vs 11%; P = 0.006), higher OM (63% vs 23%; P = 0.002), and lower RFS (38% vs 89%; P = 0.002) than those with HCC when matched for pretransplant tumor characteristics, as well as higher TR (46% vs 23%; P = 0.083), higher OM (63% vs 35%; P = 0.026), and lower RFS (38% vs 59%; P = 0.037) when matched for posttransplant tumor characteristics. Two pairings were performed to compare the outcomes of LT recipients with HCC-CC vs HCC. There was no significant difference between the outcomes in either pairing. CONCLUSION Patients with ICC had worse outcomes than patients undergoing LT for HCC. The outcomes of patients with HCC-CC did not differ significantly from those of patients with HCC.
publishDate 2022
dc.date.issued.fl_str_mv 2022
dc.date.accessioned.fl_str_mv 2023-11-11T03:24:22Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/266990
dc.identifier.issn.pt_BR.fl_str_mv 2218-4333
dc.identifier.nrb.pt_BR.fl_str_mv 001186996
identifier_str_mv 2218-4333
001186996
url http://hdl.handle.net/10183/266990
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv World journal of clinical oncology. Pleasanton. Vol. 13, no. 8 (Aug. 2022), p. 688-701
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/266990/3/001186996.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/266990/4/001186996-02.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/266990/1/001186996.pdf
http://www.lume.ufrgs.br/bitstream/10183/266990/2/001186996-02.pdf
bitstream.checksum.fl_str_mv 1774c56d95828b25a9a1f30a95fcaa78
f12c049d57793f52dc88862f548fcf8b
e0714ec145e85479ecd096ecad7b7c59
11dd34907c5d691e40a01d993a98228c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801225103435890688